top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Search

Versa Vascular Appoints Bill Shields as CEO to Drive Next Phase of Growth

Aug 13

1 min read

Santa Cruz, CA, August 11, 2026 (Business Wire) -- Versa Vascular has appointed Bill Shields as chief executive officer, bringing an experienced medical technology executive to lead the company’s next stage of growth. Shields will focus on advancing the company’s vascular technology platform and expanding its commercial reach. His appointment is expected to support broader adoption of Versa Vascular’s solutions and strengthen the company’s position in the vascular device market.

Read full article here.

Recent Posts

Superluminal Medicines Secures $60M Series B to Advance Rare Obesity Drug Into Clinical Trials

Boston, MA, September 3, 2026 (PR Newswire) -- Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners, with participation from Deep Track Capital, Per

Oligomerix Names Cara Cassino as Interim CEO to Lead Next Stage of Alzheimer’s Drug Development

Bronx, NY, August 31, 2026 (Business Wire) -- Oligomerix has appointed biopharmaceutical veteran Cara Cassino, M.D., as Interim President and CEO as the company transitions from discovery research i

NeuShen Therapeutics Raises More Than $80M in Series B to Accelerate Global CNS Drug Development

Shanghai, China and Boston, MA, September 3, 2026 (NeuShen Therapeutics) -- NeuShen Therapeutics has completed an oversubscribed Series B financing of more than $80 million to expand its central ner

Comments

Life Science Headlines

Superluminal Medicines Secures $60M Series B to Advance Rare Obesity Drug Into Clinical Trials

Oligomerix Names Cara Cassino as Interim CEO to Lead Next Stage of Alzheimer’s Drug Development

NeuShen Therapeutics Raises More Than $80M in Series B to Accelerate Global CNS Drug Development

Vivace Therapeutics Appoints New CEO as VT3989 Moves Toward Phase 3 Mesothelioma Trial

Elucid Raises $55M Series D to Expand AI-Powered Cardiovascular Imaging Platform

InduPro Raises $77M Series B to Advance Precision Oncology Pipeline

Juvena Therapeutics Appoints Julie Anne Smith as Chief Executive Officer

Amylyx Pharmaceuticals Prices Upsized $500M Public Offering to Support Pipeline Growth

Longevica Therapeutics Names Ex-Genentech Executive Prasun Mishra as CEO to Advance Longevity Drug Development

McKesson to Acquire Precision Medicine Group in $2.25B Deal to Expand Clinical Services

bottom of page